Investor Presentation on Zoetis Exclusive Global License
Brisbane, May 16, 2018 AEST (ABN Newswire) - Anatara Lifesciences (
ASX:ANR) is pleased to release a new investor presentation following the announcement that Anatara had established an exclusive licensing agreement with Zoetis Inc., the leading global animal health company, for the worldwide development, manufacture, distribution and marketing of Detach(R) as a non-antibiotic approach to aid in the control of diarrhoeal disease (known as scour) in livestock and in horses.
Key points:
- Anatara releases investor presentation containing structure and terms of its recently announced exclusive global license agreement for lead product, Detach(R) with Zoetis Inc., the leading global animal health company
The investor presentation includes additional information on the structure of the agreement, including the deal terms for up front payments and milestones, and the expected royalty range on product sales.
About Zoetis
Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2017, the company generated annual revenue of $5.3 billion with approximately 9,000 employees. For more information, visit www.zoetis.com.
To view the presentation, please visit:
http://abnnewswire.net/lnk/N411A524
About Anatara Lifesciences Limited
Anatara Lifesciences Limited (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing productsfor human and animal health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.
| ||
|
